Steady improvement seen in data from open-label extension study
Losmapimod, a drug that is currently in a Phase 3 clinical trial for FSH muscular dystrophy, continues to slow or stop the progression of disease in patients who have been taking the drug for up to 96 weeks, according to Fulcrum Therapeutics, the Cambridge, Massachusetts-based company that is developing the therapy. Jenny Shoskes, PharmD, from Fulcrum presented the data in early October at the World Muscle Society Congress in Halifax, Canada.
The data were collected from individuals who had participated in the Phase 2 study of the drug that was completed in 2021 and then opted to continue in an “open-label extension” (OLE) study in which all participants were offered losmapimod for an additional 48 weeks.
In the Phase 2 study, called ReDUX4, half of the participants were assigned at random to take 15 mg losmapimod twice daily and half received placebo. The trial was “double blind,” meaning that neither the participants nor researchers conducting the study knew who was receiving drug or placebo. At the end of the initial 48-week study period, all participants were offered the option to join the open-label extension, in which everyone who was on placebo was switched to losmapimod and all who started on losmapimod continued on losmapimod. Of the 77 participants who completed the initial 48-week study, 76 enrolled in the OLE. At week 96, 74 participants remained on treatment.
“Losmapimod can provide meaningful benefits”
In the ReDUX4 trial, individuals who had been on placebo experienced disease progression as shown by a decline in the range of motion of their arms (“reachable workspace” or RWS). From this placebo group, 36 individuals joined the open-label study and went on losmapimod for 48 weeks. This group, which had previously lost range of arm motion, demonstrated trends of slowing or stopping loss of muscle function, as measured by RWS. Participants who originally received losmapimod and remained on therapy (38 people), continued to show slowing or stopping of disease progression and demonstrated improvement in muscle function, as measured by RWS. (See graph below.)
Through the 96 weeks of the ReDUX4 and OLE study, losmapimod was generally safe and well tolerated by the participants. “No treatment-related serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) leading to study drug discontinuation were reported through 96 weeks of dosing,” Fulcrum noted.
“Every FSHD patient faces relentless and accumulating muscle and functional loss. These long-term data further demonstrate that losmapimod can provide meaningful benefits to patients living with this relentless, debilitating disease,” said Bryan Stuart, chief executive officer at Fulcrum. “The sustained ability to slow or halt the progression of FSHD over two years underscores the significance of our Phase 3 REACH trial and the potential of losmapimod to be the first approved treatment for FSHD.”
Fulcrum is currently investigating losmapimod in the ongoing Phase 3 REACH trial. For more information about the trial please visit https://clinicaltrials.gov/ct2/show/NCT05397470.